RecruitingNCT07143981

The Fecal Microbiome Transplant (FMT) Study for Anorexia Nervosa

Fecal Microbiome Transplant to Normalize Gut Microbiota, Metabolomics, Immunology, Cognitive and Affective Processing in Patients Suffering From Anorexia Nervosa


Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Enrollment

20 participants

Start Date

Jan 15, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

Anorexia Nervosa (AN) is a severe, debilitating and potentially life threatening illness that is difficult to treat. A cardinal symptom of AN is the mistaken belief on the part of the individuals that they are overweight and must continue to restrict intake. This fixed false belief is a detrimental factor to recovery. It is known that AN involves disturbance in the gut microbiome (GM; the microbes that live in the lower intestinal tract). The GM also affects how one thinks and makes food choices - there appears to be a direct link between the GM and how the brain functions. This connection is thought to occur through chemical processes that convey information from the gut to the brain. It is known that fecal microbiome transplant (FMT) has been useful in treating several illnesses, including several mental illnesses. The investigators intend to deliver FMT to individuals with AN to determine the extent to which this modifies their GM, their biochemistry, their thinking processes and their moods and emotions. The investigators believe this will illuminate important aspects of AN that keep the illness in place, and that this will uncover useful approaches to better treat it.


Eligibility

Min Age: 16 YearsMax Age: 35 Years

Inclusion Criteria3

  • meet DSM 5 criteria for AN, restricting type, moderate or higher severity, as indicated by a BMI\<17
  • Participants must we willing and able to swallow FMT capsules without vomiting
  • Able to read and understand conversational English

Exclusion Criteria7

  • Medical or psychiatric instability needing hospitalization
  • Patients with AN binge/purge type
  • Use of antibiotics or probiotics in the month prior to treatment
  • Regular oral steroid use, or potent topical steroid use on large sections of skin
  • Chronic immune compromise and chronic illness affecting the intestinal tract or metabolic health
  • Pregnancy or intended pregnancy over the time of study
  • Patients enrolled in any treatment program that involves refeeding

Locations(1)

London Health Sciences Research Institute

London, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07143981


Related Trials